688488 艾迪药业
午间休市 04-14 11:29:59
资讯
新帖
简况
每周股票复盘：艾迪药业（688488）ACC085注射液获临床试验批准
证券之星 · 04-12 02:06
每周股票复盘：艾迪药业（688488）ACC085注射液获临床试验批准
艾迪药业（688488）披露ACC085注射液获临床试验批准通知书，4月7日股价下跌0.81%
中金财经 · 04-07
艾迪药业（688488）披露ACC085注射液获临床试验批准通知书，4月7日股价下跌0.81%
艾迪药业最新公告：ACC085注射液获药物临床试验批准
证券之星 · 04-06
艾迪药业最新公告：ACC085注射液获药物临床试验批准
每周股票复盘：艾迪药业（688488）周内股价大涨15%登龙虎榜
证券之星 · 04-05
每周股票复盘：艾迪药业（688488）周内股价大涨15%登龙虎榜
艾迪药业：3月31日董事傅和亮增持股份合计13.35万股
证券之星 · 04-01
艾迪药业：3月31日董事傅和亮增持股份合计13.35万股
4月1日艾迪药业（688488）龙虎榜数据：机构净买入3066.93万元，北向资金净买入1217.41万元
证券之星 · 04-01
4月1日艾迪药业（688488）龙虎榜数据：机构净买入3066.93万元，北向资金净买入1217.41万元
图解艾迪药业年报：第四季度单季净利润同比增长84.19%
证券之星 · 03-31
图解艾迪药业年报：第四季度单季净利润同比增长84.19%
每周股票复盘：艾迪药业（688488）拟13,005.9540万元收购南大药业22.2324%股权
证券之星 · 03-29
每周股票复盘：艾迪药业（688488）拟13,005.9540万元收购南大药业22.2324%股权
艾迪药业（688488）披露收购控股子公司少数股东股权进展公告，3月27日股价上涨4.98%
证券之星 · 03-27
艾迪药业（688488）披露收购控股子公司少数股东股权进展公告，3月27日股价上涨4.98%
艾迪药业最新公告：用于治疗HIV感染的多替拉韦钠片获得药品注册批准
中金财经 · 03-15
艾迪药业最新公告：用于治疗HIV感染的多替拉韦钠片获得药品注册批准
艾迪药业：整合酶抑制剂已成为全球抗艾主流治疗方案之一
证券日报 · 03-13
艾迪药业：整合酶抑制剂已成为全球抗艾主流治疗方案之一
艾迪药业定增扩围背后的两难：填补巨亏窟窿，能否赌出一个未来？
新浪证券 · 03-12
艾迪药业定增扩围背后的两难：填补巨亏窟窿，能否赌出一个未来？
艾迪药业：3月9日高管傅和亮增持股份合计6.88万股
证券之星 · 03-09
艾迪药业：3月9日高管傅和亮增持股份合计6.88万股
艾迪药业：3月5日高管傅和亮增持股份合计5.31万股
证券之星 · 03-06
艾迪药业：3月5日高管傅和亮增持股份合计5.31万股
艾迪药业（688488）披露2026年度向特定对象发行A股股票预案，3月3日股价下跌1.49%
证券之星 · 03-03
艾迪药业（688488）披露2026年度向特定对象发行A股股票预案，3月3日股价下跌1.49%
艾迪药业拟非公开发行募资不超过13亿元 用于项目投资、股权收购及补充流动资金
美股速递 · 03-02
艾迪药业拟非公开发行募资不超过13亿元 用于项目投资、股权收购及补充流动资金
艾迪药业（688488）披露实际控制人增持股份计划公告，3月2日股价上涨3.13%
证券之星 · 03-02
艾迪药业（688488）披露实际控制人增持股份计划公告，3月2日股价上涨3.13%
艾迪药业(688488.SH)实控人之一傅和亮拟1000万元至1500万元增持公司股份
智通财经 · 03-01
艾迪药业(688488.SH)实控人之一傅和亮拟1000万元至1500万元增持公司股份
每周股票复盘：艾迪药业（688488）2025年净亏损1973万同比收窄86.02%
证券之星 · 03-01
每周股票复盘：艾迪药业（688488）2025年净亏损1973万同比收窄86.02%
艾迪药业(688488.SH)2025年度营业总收入7.21亿元 同比增加72.49%
智通财经 · 02-24
艾迪药业(688488.SH)2025年度营业总收入7.21亿元 同比增加72.49%
暂无数据
公司概况
公司名称：
江苏艾迪药业集团股份有限公司
所属行业：
其他制造业
上市日期：
2020-07-20
主营业务：
江苏艾迪药业集团股份有限公司的主营业务是抗HIV药物和人源蛋白领域药物的研发、生产及销售。公司的主要产品是乌司他丁粗品、其他人源蛋白粗品、HIV新药(艾诺韦林片)、HIV新药(艾诺米替片)、番泻叶颗粒、蜡样芽孢杆菌片、HIV诊断试剂、药品（尿激酶针剂）、低分子量肝素钠及其他。
发行价格：
13.99
{"stockData":{"symbol":"688488","market":"SH","secType":"STK","nameCN":"艾迪药业","latestPrice":18.67,"timestamp":1776137399000,"preClose":18.48,"halted":0,"volume":8101376,"delay":0,"changeRate":0.0103,"floatShares":421000000,"shares":421000000,"eps":0.2428,"marketStatus":"午间休市","change":0.19,"latestTime":"04-14 11:29:59","open":18.8,"high":18.86,"low":18.16,"amount":150000000,"amplitude":0.0379,"askPrice":18.79,"askSize":13,"bidPrice":18.67,"bidSize":19,"shortable":0,"etf":0,"ttmEps":0.2428,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776142800000},"marketStatusCode":3,"adr":0,"adjPreClose":18.48,"symbolType":"stock_kcb","openAndCloseTimeList":[[1776130200000,1776137400000],[1776142800000,1776150000000]],"highLimit":20.33,"lowLimit":16.63,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":420782808,"isCdr":false,"pbRate":8.06,"roa":"--","peRate":76.894563,"roe":"--","epsLYR":-0.05,"committee":-0.464567,"marketValue":7856000000,"turnoverRate":0.0193,"status":0,"floatMarketCap":7856000000},"requestUrl":"/m/hq/s/688488/tweets","defaultTab":"tweets","newsList":[{"id":"2626112210","title":"每周股票复盘：艾迪药业（688488）ACC085注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626112210","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626112210?lang=zh_cn&edition=full","pubTime":"2026-04-12 02:06","pubTimestamp":1775930773,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘，艾迪药业报收于18.48元，较上周的18.43元上涨0.27%。本周，艾迪药业4月7日盘中最高价报19.68元。艾迪药业当前最新总市值77.76亿元，在生物制品板块市值排名34/51，在两市A股市值排名2434/5196。ACC085为全新化学结构的HIV-1衣壳功能抑制剂，临床前研究显示其对多种HIV-1病毒株及耐药株具有良好的抗病毒活性，并具备长效潜力。公司后续将推进临床试验工作，产品上市尚需进一步审评审批，且对公司近期业绩无重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625931146","title":"艾迪药业（688488）披露ACC085注射液获临床试验批准通知书，4月7日股价下跌0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625931146","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625931146?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:07","pubTimestamp":1775556431,"startTime":"0","endTime":"0","summary":"艾迪药业于近日披露《关于ACC085注射液获得药物临床试验批准通知书的自愿性披露公告》。公告显示，江苏艾迪药业集团股份有限公司及全资子公司泸州艾迪医药技术有限公司近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司自主研发的1类新药ACC085注射液开展用于HIV-1感染风险人群暴露前预防的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260407/32128552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625762005","title":"艾迪药业最新公告：ACC085注射液获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2625762005","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625762005?lang=zh_cn&edition=full","pubTime":"2026-04-06 16:20","pubTimestamp":1775463649,"startTime":"0","endTime":"0","summary":"艾迪药业公告称，公司及全资子公司近日收到国家药监局核准签发的《药物临床试验批准通知书》，同意公司抗艾滋病领域在研1类新药ACC085注射液开展临床试验。ACC085是公司自主研发的全新化学结构的HIV-1衣壳功能抑制剂，临床前研究显示其具有良好的抗病毒活性及长效潜力。公司表示，该事项对近期业绩不会产生重大影响，后续尚需开展临床试验并经审评审批通过后方可生产上市，存在市场竞争、政策变化等风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040600001941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625261647","title":"每周股票复盘：艾迪药业（688488）周内股价大涨15%登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2625261647","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625261647?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:15","pubTimestamp":1775326513,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，艾迪药业报收于18.43元，较上周的16.02元上涨15.04%。本周，艾迪药业4月3日盘中最高价报18.84元。本周关注点来自交易信息汇总：艾迪药业因日收盘价涨幅达15%登上龙虎榜。交易信息汇总沪深交易所2026年4月1日公布的交易公开信息显示，艾迪药业因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624513696","title":"艾迪药业：3月31日董事傅和亮增持股份合计13.35万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624513696","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624513696?lang=zh_cn&edition=full","pubTime":"2026-04-01 20:01","pubTimestamp":1775044864,"startTime":"0","endTime":"0","summary":"证券之星消息，根据4月1日市场公开信息、上市公司公告及交易所披露数据整理，艾迪药业最新董监高及相关人员股份变动情况：2026年3月31日公司董事,核心技术人员傅和亮共增持公司股份13.35万股，占公司总股本为0.0317%。变动期间公司股价下跌4.26%，3月31日当日收盘报14.85元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100038917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624599492","title":"4月1日艾迪药业（688488）龙虎榜数据：机构净买入3066.93万元，北向资金净买入1217.41万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624599492","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624599492?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:21","pubTimestamp":1775035272,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年4月1日公布的交易公开信息显示，艾迪药业因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年4月1日收盘，艾迪药业报收于17.82元，上涨20.0%，换手率6.8%，成交量28.62万手，成交额4.85亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入3066.93万元，北向资金合计净买入1217.41万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100031660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623323265","title":"图解艾迪药业年报：第四季度单季净利润同比增长84.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623323265","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623323265?lang=zh_cn&edition=full","pubTime":"2026-03-31 02:29","pubTimestamp":1774895383,"startTime":"0","endTime":"0","summary":"证券之星消息，艾迪药业2025年年报显示，当年度公司主营收入7.19亿元，同比上升72.13%；归母净利润-1953.23万元，同比上升86.17%；扣非净利润-2059.66万元，同比上升86.13%；其中2025年第四季度，公司单季度主营收入1.67亿元，同比上升40.23%；单季度归母净利润-1269.18万元，同比上升84.19%；单季度扣非净利润-198.44万元，同比上升96.94%；负债率43.89%，投资收益-73.63万元，财务费用1371.87万元，毛利率66.79%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033100005632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623333805","title":"每周股票复盘：艾迪药业（688488）拟13,005.9540万元收购南大药业22.2324%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2623333805","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623333805?lang=zh_cn&edition=full","pubTime":"2026-03-29 03:53","pubTimestamp":1774727587,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，艾迪药业报收于16.02元，较上周的15.55元上涨3.02%。本周，艾迪药业3月27日盘中最高价报16.17元。3月23日盘中最低价报14.4元。艾迪药业当前最新总市值67.41亿元，在生物制品板块市值排名36/51，在两市A股市值排名2690/5191。工商变更将在首期款支付后60个工作日内完成。姚繁狄的交易安排仍按原协议执行。本次交易不构成重大资产重组，无需提交股东会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622878662","title":"艾迪药业（688488）披露收购控股子公司少数股东股权进展公告，3月27日股价上涨4.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622878662","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622878662?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:29","pubTimestamp":1774621786,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，艾迪药业报收于16.02元，较前一交易日上涨4.98%，最新总市值为67.41亿元。近日，艾迪药业发布《关于公司收购控股子公司少数股东股权进展的公告》。公告显示，江苏艾迪药业集团股份有限公司拟以13,005.9540万元收购控股子公司南京南大药业有限责任公司少数股东华泰国信、道兴创投及姚繁狄合计持有的22.2324%股权。姚繁狄的交易安排仍按原协议执行。本次交易不构成重大资产重组，无需提交股东会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700050221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619108165","title":"艾迪药业最新公告：用于治疗HIV感染的多替拉韦钠片获得药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619108165","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619108165?lang=zh_cn&edition=full","pubTime":"2026-03-15 16:02","pubTimestamp":1773561722,"startTime":"0","endTime":"0","summary":"艾迪药业公告称，公司收到国家药监局核准签发的多替拉韦钠片《药品注册证书》。多替拉韦钠片仿制药获批上市，将丰富公司抗艾滋病药品种类及临床方案，与公司当前已上市的非核苷类逆转录抗HIV药物形成有效互补，提升公司核心竞争力，对公司未来的经营业绩有积极的影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260315/32069374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619911201","title":"艾迪药业：整合酶抑制剂已成为全球抗艾主流治疗方案之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2619911201","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619911201?lang=zh_cn&edition=full","pubTime":"2026-03-13 19:12","pubTimestamp":1773400320,"startTime":"0","endTime":"0","summary":"证券日报网3月13日讯 ，艾迪药业在接受调研者提问时表示，目前，整合酶抑制剂已成为全球抗艾主流治疗方案之一。根据美国公开市场资料和相关上市公司数据，整合酶抑制剂主导美国抗HIV药物市场，销售额持续攀升。吉利德、葛兰素史克等公司旗下相关产品，美国销售额从2022年的154.87亿美元增至2025年的197.27亿美元，印证该品类在全球市场的高认可度与巨大需求空间。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-13/doc-inhqvxrm4057755.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-13/doc-inhqvxrm4057755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618182245","title":"艾迪药业定增扩围背后的两难：填补巨亏窟窿，能否赌出一个未来？","url":"https://stock-news.laohu8.com/highlight/detail?id=2618182245","media":"新浪证券","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618182245?lang=zh_cn&edition=full","pubTime":"2026-03-12 17:09","pubTimestamp":1773306540,"startTime":"0","endTime":"0","summary":"3月初，艾迪药业抛出一份上限达12.77亿元的新定增预案，而就在年初，这一数字还停留在1.85亿元。募资额的大幅膨胀，直观地揭示了这家创新药企当前的生存状态：一边是连年亏损留下的资金窟窿亟待填补，另一边是研发竞赛和商业化扩张的巨额开销必须支付。 艾迪药业面临的第一个考验，也是最直观的风险，在于其财务数据的严重背离。对于艾迪药业而言，此次定增能否顺利落地只是第一步。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-03-12/doc-inhqtqkm8491648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618625522","title":"艾迪药业：3月9日高管傅和亮增持股份合计6.88万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618625522","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618625522?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:01","pubTimestamp":1773057709,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月9日市场公开信息、上市公司公告及交易所披露数据整理，艾迪药业最新董监高及相关人员股份变动情况：2026年3月9日公司董事,核心技术人员傅和亮共增持公司股份6.88万股，占公司总股本为0.0164%。艾迪药业近半年内的董监高及核心技术人员增减持详情如下：艾迪药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入1775.31万，融资余额增加；融券净流入1.4万，融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900030522.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617687814","title":"艾迪药业：3月5日高管傅和亮增持股份合计5.31万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617687814","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617687814?lang=zh_cn&edition=full","pubTime":"2026-03-06 20:01","pubTimestamp":1772798507,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月6日市场公开信息、上市公司公告及交易所披露数据整理，艾迪药业最新董监高及相关人员股份变动情况：2026年3月5日公司董事,核心技术人员傅和亮共增持公司股份5.31万股，占公司总股本为0.0126%。艾迪药业近半年内的董监高及核心技术人员增减持详情如下：艾迪药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入1374.08万，融资余额增加；融券净流入1.4万，融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600035771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616343116","title":"艾迪药业（688488）披露2026年度向特定对象发行A股股票预案，3月3日股价下跌1.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616343116","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616343116?lang=zh_cn&edition=full","pubTime":"2026-03-03 17:52","pubTimestamp":1772531524,"startTime":"0","endTime":"0","summary":"截至2026年3月3日收盘，艾迪药业报收于16.57元，较前一交易日下跌1.49%，最新总市值为69.72亿元。该股当日开盘16.78元，最高17.41元，最低16.47元，成交额达2.03亿元，换手率为2.85%。近日，江苏艾迪药业集团股份有限公司披露《2026年度向特定对象发行A股股票预案》。公告显示，公司拟向特定对象发行A股股票，募集资金总额不超过127,675.64万元，用于新型HIV整合酶抑制剂全球临床开发项目、收购南大药业22.2324%股权及补充流动资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300032032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","159982","BK0262","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158372486","title":"艾迪药业拟非公开发行募资不超过13亿元 用于项目投资、股权收购及补充流动资金","url":"https://stock-news.laohu8.com/highlight/detail?id=1158372486","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158372486?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:15","pubTimestamp":1772453735,"startTime":"0","endTime":"0","summary":"艾迪药业宣布，公司计划通过非公开发行股票的方式，募集资金总额不超过13亿元人民币。此次募资将主要用于支持特定项目的建设与发展、进行相关股权收购，以及补充公司的营运资金，以进一步增强企业资本实力和业务拓展能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616380381","title":"艾迪药业（688488）披露实际控制人增持股份计划公告，3月2日股价上涨3.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616380381","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616380381?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:41","pubTimestamp":1772444467,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，艾迪药业报收于16.82元，较前一交易日上涨3.13%，最新总市值为70.78亿元。该股当日开盘16.31元，最高17.48元，最低16.23元，成交额达1.96亿元，换手率为2.74%。近日，艾迪药业发布《关于实际控制人增持股份计划的公告》。本次增持不设价格区间，增持期间及法定期限内不减持所持股份。增持计划实施后不会导致公司控股股东或实际控制人变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200026435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616829386","title":"艾迪药业(688488.SH)实控人之一傅和亮拟1000万元至1500万元增持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2616829386","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616829386?lang=zh_cn&edition=full","pubTime":"2026-03-01 17:05","pubTimestamp":1772355920,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾迪药业(688488.SH)发布公告，公司实际控制人之一、董事长傅和亮先生(以下简称“增持主体”)拟自2026年3月2日起6个月内，通过上海证券交易所交易系统允许的方式(包括但不限于集中竞价和大宗交易)增持公司股份，计划增持金额不低于人民币1,000万元(含)且不超过人民币1,500万元(含)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616843059","title":"每周股票复盘：艾迪药业（688488）2025年净亏损1973万同比收窄86.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843059","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843059?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:28","pubTimestamp":1772303292,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，艾迪药业报收于16.31元，较上周的17.5元下跌6.8%。本周，艾迪药业2月24日盘中最高价报17.78元。公司公告汇总艾迪药业2025年度业绩快报公告江苏艾迪药业集团股份有限公司发布2025年度业绩快报。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613579151","title":"艾迪药业(688488.SH)2025年度营业总收入7.21亿元 同比增加72.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613579151","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613579151?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:33","pubTimestamp":1771925590,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾迪药业(688488.SH)发布2025年度业绩快报，报告期内，公司营业总收入7.21亿元，较上年同期增加72.49%。归属于母公司所有者的净利润-1,973.37万元，较上年同期相比，亏损幅度同比下降86.02%。主要原因如下：(1)报告期内因抗HIV创新药收入的增加、合并南大药业的经营数据等原因，导致主营业务毛利较上年同期增加了约25,500万元;(2)报告期内因公司加大新药推广力度、合并南大药业的经营数据等原因，本期销售费用支出较上年同期增加了约9,200万元;(3)报告期内公司因市场开拓与预期变化趋于平稳，本期的资产减值损失较上年同期减少了约4,800万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776138477435,"stockEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":0.1528},{"period":"3month","weight":0.0877},{"period":"6month","weight":0.2255},{"period":"1year","weight":0.5503},{"period":"ytd","weight":0.1317}],"compareEarnings":[{"period":"1week","weight":0.028},{"period":"1month","weight":-0.0261},{"period":"3month","weight":-0.0363},{"period":"6month","weight":0.0195},{"period":"1year","weight":0.2317},{"period":"ytd","weight":0.005}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏艾迪药业集团股份有限公司","boardCode":"AI0041","boardName":"其他制造业","stockholders":"10901人(较上一季度增加9.48%)","perCapita":"38600股","listingDate":"2020-07-20","address":"江苏省扬州市邗江区新甘泉西路69号","registeredCapital":"42078万元","survey":" 江苏艾迪药业集团股份有限公司的主营业务是抗HIV药物和人源蛋白领域药物的研发、生产及销售。公司的主要产品是乌司他丁粗品、其他人源蛋白粗品、HIV新药(艾诺韦林片)、HIV新药(艾诺米替片)、番泻叶颗粒、蜡样芽孢杆菌片、HIV诊断试剂、药品（尿激酶针剂）、低分子量肝素钠及其他。","listedPrice":13.99},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾迪药业(688488)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾迪药业(688488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾迪药业,688488,艾迪药业股票,艾迪药业股票老虎,艾迪药业股票老虎国际,艾迪药业行情,艾迪药业股票行情,艾迪药业股价,艾迪药业股市,艾迪药业股票价格,艾迪药业股票交易,艾迪药业股票购买,艾迪药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾迪药业(688488)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾迪药业(688488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}